(News Bulletin 247) – Acticor Biotech, a company specializing in the development of glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, today announces the results of its collaboration with Brainomix Limited for artificial intelligence (AI) analysis ) brain imaging results of patients with stroke in a phase 1b/2a ACTIMIS study.
‘The preliminary results seem to show that glenzocimab not only reduces the occurrence of intracranial hemorrhages, but also their volume, compared to placebo’, highlights Yannick Pletan, Deputy CEO and Medical Director of Acticor Biotech.
‘This analysis carried out in our laboratories allowed us to precisely identify the mode of action and to show the effectiveness of glenzocimab. It also demonstrated that glenzocimab reduced the size of brain lesions after thrombolysis in stroke and identified subgroups of patients who appear to derive greater clinical benefit from it,” adds George Harston, Medical Director of Brainomix. and Consulting Physician specializing in Stroke.
Therefore, the biopharmaceutical company advises that the results of the ACTIMIS study will be submitted for publication at upcoming international congresses.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
